SCHEMBL29437965

SCHEMBL29437965

CC[C@@](C)(NC(=O)OC(C)(C)C)C(=O)Nc1ccc(Oc2ccc(C)c(OC)c2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
ALDH1A1 P00352 3/20 0.39
GFER P55789 1/20 0.39
MAPK1 P28482 2/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
PABPC1 P11940 3/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19749963 1.00 MAPT (0.39) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL15308385 1.00 MAPT (0.39) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL17180635 0.92 MAPT (0.43) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL13268395 0.89 SMN1; SMN2 (0.40) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL23927067 0.88 MAPT (0.44) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL30258055 0.88 MAPT (0.44) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL9923944 0.87 MAPT (0.44) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL13832477 0.87 MAPT (0.40) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL1979711 0.84 MAPT (0.42) MAPTALDH1A1GFERMAPK1GAA
SCHEMBL1979709 0.84 MAPT (0.42) MAPTALDH1A1GFERMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MAPT 3926/4885ALDH1A1 1966/4885GFER 2690/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MAPT 3926/4885ALDH1A1 1966/4885GFER 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.